<DOC>
	<DOCNO>NCT02411955</DOCNO>
	<brief_summary>The purpose study evaluate therapeutic equivalence safety Tazarotene Cream 0.1 % Tazorac® ( tazarotene cream 0.1 % ) .</brief_summary>
	<brief_title>A Study Comparing Tazarotene Cream 0.1 % Tazorac® Both Placebo Control Treatment Acne Vulgaris</brief_title>
	<detailed_description>The purpose study evaluate therapeutic equivalence safety Tazarotene Cream 0.1 % Tazorac® ( tazarotene cream 0.1 % ) treatment acne vulgaris demonstrate superiority test reference product placebo control .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Healthy male nonpregnant female age ≥ 12 ≤ 40 year clinical diagnosis acne vulgaris . Subjects age 18 year old must provide write consent . Subjects age 12 17 year must provide write assent accompany write consent legally acceptable representative . All subject legally acceptable representative must sign Health Insurance Portability Accountability Act authorization . Must minimum ≥ 25 noninflammatory lesion ≥ 20 inflammatory lesion ≤ 2 nodulocystic lesion baseline face . Must definite clinical diagnosis acne vulgaris severity grade 2 , 3 , 4 per Investigator 's Global Assessment . Female subject pregnant , nurse plan become pregnant study participation . Have history hypersensitivity allergy tazarotene , retinoids and/or study medication ingredient . Presence skin condition would interfere diagnosis assessment acne vulgaris .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>